Essex Investment Management’s Teva Pharmaceuticals TEVA Stock Holding History

Essex Investment Management’s Portfolio TEVA Stock Details TEVA Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2019 Q1	–	Sell	-23,630	Closed	-$364K	–	512
2018 Q4	$364K	Hold	23,630	–	–	0.06%	271
2018 Q3	$509K	Buy	+23,630	New	+$549K	0.06%	294
2016 Q3	–	Sell	-19,336	Closed	-$971K	–	357
2016 Q2	$971K	Hold	19,336	–	–	0.16%	143
2016 Q1	$1.03M	Sell	19,336 -2,451	-11%	-$144K	0.18%	126
2015 Q4	$1.43M	Sell	21,787 -35,821	-62%	-$2.21M	0.22%	106
2015 Q3	$3.25M	Buy	+57,608	New	+$3.74M	0.53%	46
2015 Q2	–	Sell	-24,422	Closed	-$1.52M	–	336
2015 Q1	$1.52M	Hold	24,422	–	–	0.21%	105
2014 Q4	$1.41M	Hold	24,422	–	–	0.2%	113
2014 Q3	$1.31M	Hold	24,422	–	–	0.2%	125
2014 Q2	$1.28M	Hold	24,422	–	–	0.19%	147
2014 Q1	$1.29M	Buy	+24,422	New	+$1.13M	0.19%	165

Other funds holding TEVA

Capital Research Global Investors Los Angeles, California $645B AUM 30.41% 1-Year Est. Return

Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return

Berkshire Hathaway Omaha, Nebraska $263B AUM 16.68% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

ACM

Abrams Capital Management Boston, Massachusetts $4.64B AUM 1.52% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

AllianceBernstein Nashville, Tennessee $309B AUM 23.92% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Essex Investment Management's TEVA Position: Q1 2019 in Review

Essex Investment Management sold out of Teva Pharmaceuticals (TEVA) in Q1 2019, closing a stake of 23,630 shares — an estimated $364K sold.

Essex Investment Management first reported a position in TEVA in Q1 2014 and held it in 11 quarters. The position peaked at $3.25M in Q3 2015. 522 funds tracked by Wall St. Rank hold TEVA as of Q1 2019.

Essex Investment Management reported no remaining Teva Pharmaceuticals position as of Q1 2019 after selling out during the quarter.
Essex Investment Management sold 23,630 Teva Pharmaceuticals shares in Q1 2019, an estimated $364K.
Essex Investment Management first reported a position in Teva Pharmaceuticals in Q1 2014 and held it in 11 quarters.
Essex Investment Management's Teva Pharmaceuticals position peaked at $3.25M in Q3 2015.
522 funds tracked by Wall St. Rank held Teva Pharmaceuticals as of Q1 2019.

Based on Essex Investment Management's 13F filing for Q1 2019, filed 15 May 2019.